89bio, Inc. Common Stock

ETNB

...

ETNB: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Show ETNB Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of ETNB by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ETNB's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on ETNB's company Twitter account

WallStreetBets

Number of mentions of ETNB in WallStreetBets Daily Discussion

ETNB News

Recent insights relating to ETNB

CNBC Recommendations

Recent picks made for ETNB stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ETNB

Corporate Flights

Flights by private jets registered to ETNB